Találati lista | Tudóstér

001-es BibID:	BIBFORM091345
Első szerző:	Szöőr Árpád (orvos)
Cím:	From antibodies to living drugs : quo vadis cancer immunotherapy? / Szöőr Árpád, Szöllősi János, Vereb György
Dátum:	2021
ISSN:	2676-8615 2676-8607
Megjegyzések:	In the last few decades, monoclonal antibodies targeting various receptors and ligands have shown signifcant advance in cancer therapy. However, still a great percentage of patients experiences tumor relapse despite persistent antigen expression. Immune cell therapy with adoptively transferred modifed T cells that express chimeric antigen receptors (CAR) is an engaging option to improve disease outcome. Designer T cells have been applied with remarkable success in the treatment for acute B cell leukemias, yielding unprecedented antitumor activity and signifcantly improved overall survival. Relying on the success of CAR T cells in leukemias, solid tumors are now emerging potential targets; however, their complexity represents a signifcant challenge. In preclinical models, CAR T cells recognized and efciently killed the wide spectrum of tumor xenografts; however, in human clinical trials, limited antitumor efcacy and serious side efects, including cytokine release syndrome, have emerged as potential limitations. The next decade will be an exciting time to further optimize this novel cellular therapeutics to improve efector functions and, at the same time, keep adverse events in check. Moreover, we need to establish whether gene-modifed T cells which are yet exclusively used for cancer patients could also be successful in the treatment for other diseases. Here, we provide a concise overview about the transition from monoclonal antibodies to the generation of chimeric antigen receptor T cells. We summarize lessons learned from preclinical models, including our own HER2-positive tumor models, as well as from clinical trials worldwide. We also discuss the challenges we are facing today and outline future prospects taa, km
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Chimeric autoantibody receptor Immunotherapy Chimeric antigen receptor Bispecifc antibody Cell therapy Humanized antibody
Megjelenés:	Biologia Futura. - 72 : 1 (2021), p. 85-99. -
További szerzők:	Szöllősi János (1953-) (biofizikus) Vereb György (1965-) (biofizikus, orvos)
Pályázati támogatás:	K119690 OTKA FK132773 OTKA GINOP-2.3.2-15-2016-00044 GINOP Egyéb MTA ÚNKP-20-5-DE-48 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM094330
Első szerző:	Varga Zoltán (biofizikus, szakfordító)
Cím:	The Kv1.3 K+ channel in the immune system and its "precision pharmacology" using peptide toxins / Varga Zoltan, Tajti Gabor, Panyi Gyorgy
Dátum:	2021
ISSN:	2676-8615 2676-8607
Megjegyzések:	Since the discovery of the Kv1.3 voltage-gated K+ channel in human T cells in 1984, ion channels are considered crucial elements of the signal transduction machinery in the immune system. Our knowledge about Kv1.3 and its inhibitors is outstanding, motivated by their potential application in autoimmune diseases mediated by Kv1.3 overexpressing efector memory T cells (e.g., Multiple Sclerosis). High afnity Kv1.3 inhibitors are either small organic molecules (e.g., Pap-1) or peptides isolated from venomous animals. To date, the highest afnity Kv1.3 inhibitors with the best Kv1.3 selectivity are the engineered analogues of the sea anemone peptide ShK (e.g., ShK-186), the engineered scorpion toxin HsTx1[R14A] and the natural scorpion toxin Vm24. These peptides inhibit Kv1.3 in picomolar concentrations and are several thousand-fold selective for Kv1.3 over other biologically critical ion channels. Despite the signifcant progress in the feld of Kv1.3 molecular pharmacology several progressive questions remain to be elucidated and discussed here. These include the conjugation of the peptides to carriers to increase the residency time of the peptides in the circulation (e.g., PEGylation and engineering the peptides into antibodies), use of rational drug design to create novel peptide inhibitors and understanding the potential of-target efects of Kv1.3 inhibition.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Kv1.3 Toxin Mutation Increase in selectivity Pharmacological tailoring
Megjelenés:	Biologia Futura. - 72 : 1 (2021), p. 75-83. -
További szerzők:	Tajti Gábor (1988-) (gyógyszerész, biofizikus, sejtbiológus) Panyi György (1966-) (biofizikus)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00015 GINOP EFOP-3.6.2-16-2017-00006 EFOP K119417 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: